FY2024 EPS Estimates for Revvity, Inc. (NYSE:RVTY) Lifted by Zacks Research

Revvity, Inc. (NYSE:RVTY) – Investment analysts at Zacks Research increased their FY2024 earnings per share estimates for Revvity in a research note issued on Monday, May 20th. Zacks Research analyst I. Bandyopadhyay now anticipates that the company will post earnings per share of $4.64 for the year, up from their previous estimate of $4.62. The consensus estimate for Revvity’s current full-year earnings is $4.66 per share. Zacks Research also issued estimates for Revvity’s Q4 2024 earnings at $1.35 EPS, Q1 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.32 EPS, Q1 2026 earnings at $1.31 EPS and FY2026 earnings at $5.67 EPS.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Monday, April 29th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.04. The business had revenue of $649.90 million during the quarter, compared to analysts’ expectations of $646.83 million. Revvity had a return on equity of 7.37% and a net margin of 5.49%. The business’s revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.01 earnings per share.

Several other analysts have also recently commented on RVTY. Robert W. Baird boosted their price target on Revvity from $126.00 to $127.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 30th. Stifel Nicolaus boosted their price target on Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a research report on Friday, February 2nd. KeyCorp boosted their price target on Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. Barclays boosted their price target on Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. Finally, Raymond James boosted their price target on Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Revvity has an average rating of “Moderate Buy” and an average target price of $118.17.

Revvity Stock Up 1.1 %

Shares of RVTY opened at $113.23 on Tuesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.92 and a current ratio of 2.23. Revvity has a one year low of $79.50 and a one year high of $131.96. The stock has a market capitalization of $13.97 billion, a price-to-earnings ratio of 93.58, a PEG ratio of 2.87 and a beta of 1.09. The stock has a 50 day moving average price of $104.34 and a 200 day moving average price of $102.36.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Stockholders of record on Friday, July 19th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, July 19th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.25%. Revvity’s payout ratio is currently 23.14%.

Institutional Trading of Revvity

Large investors have recently made changes to their positions in the company. Byrne Asset Management LLC acquired a new position in Revvity during the fourth quarter worth $1,112,000. BNP Paribas Financial Markets acquired a new position in shares of Revvity in the fourth quarter worth $12,039,000. State of Michigan Retirement System acquired a new position in Revvity in the fourth quarter valued at $3,688,000. Gulf International Bank UK Ltd acquired a new position in Revvity in the fourth quarter valued at $1,136,000. Finally, Russell Investments Group Ltd. acquired a new position in Revvity in the fourth quarter valued at $10,291,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.